{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:04:25Z","timestamp":1794711865090,"version":"4.9.1"},"reference-count":109,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,6,6]],"date-time":"2008-06-06T00:00:00Z","timestamp":1212710400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2008,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background and Aim:\u2002<\/jats:bold> Current practice guidelines recommend that individuals chronically infected with the hepatitis C virus (HCV) be treated with pegylated interferon plus ribavirin. Ribavirin, however, is associated with serious adverse events (AE), especially anemia. We review its mechanism of action, its importance in treating chronic hepatitis C (CHC) patients, the AE associated with its use, and techniques used to lessen these AE.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Medline searches were performed using the keywords ribavirin and hepatitis, together with the keywords mechanism, anemia, liver transplant, renal function, pharmacokinetics, and dose reduction. Searches of abstracts of recent Digestive Diseases Week, American Association for the Study of Liver Diseases, and European Association for the Study of Liver Diseases meetings were also performed.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Ribavirin may be effective in treating CHC by affecting the virus or the host; for example by inducing viral mutations, blocking cellular enzymes, or affecting the host immune response. Although the pegylated interferons are the primary drugs used to treat CHC, a combination with ribavirin is more effective than pegylated interferon alone. Ribavirin\u2010associated AE may be lessened by ribavirin dose reductions and by maintenance of the hematocrit.<\/jats:p><jats:p><jats:bold>Conclusions:\u2002<\/jats:bold> Treatments of ribavirin toxicities, especially anemia, can allow patients to continue full\u2010dose combination therapy with peginterferon and ribavirin, enhancing their probability of attaining a sustained virologic response (SVR). Treatment of CHC should be tailored to individual patients, especially those with renal dysfunction, and should include agents that treat the side\u2010effects of CHC treatment. Monitoring of plasma ribavirin concentrations during treatment may help in the future.<\/jats:p>","DOI":"10.1111\/j.1440-1746.2008.05398.x","type":"journal-article","created":{"date-parts":[[2008,6,6]],"date-time":"2008-06-06T09:05:38Z","timestamp":1212743138000},"page":"844-855","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Ribavirin in the treatment of chronic hepatitis C"],"prefix":"10.1111","volume":"23","author":[{"given":"Paul","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,6,6]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20119"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16661"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020047"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-5-200403020-00010"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"e_1_2_8_7_2","volume-title":"Copegus [Package Insert].","year":"2004"},{"key":"e_1_2_8_8_2","volume-title":"Rebetol [Package Insert].","year":"2003"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2451"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00186.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1998.00836.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01780.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.1.124-129.2003"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02704.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200010000-00010"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.127112"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200212000-00004"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.2003.00475.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/82191"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111085598"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C100349200"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840380413"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00531.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1159\/000095155"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.1.481-488.2003"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2006.39.1.009"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00790-06"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M400460200"},{"key":"e_1_2_8_29_2","first-page":"615A","article-title":"Effect of an IMPDH inhibitor, merimepodib (MMPD), assessed alone and in combination with ribavirin, on HCV replication: implications regarding ribavirin's mechanism of action","volume":"44","author":"Hezode C","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.035"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.005"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.3.1943-1947.2005"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.105.020057"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01468.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01970.x"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10264"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02256611"},{"key":"e_1_2_8_38_2","first-page":"547","article-title":"Up\u2010regulation of IL\u201018 by interferon alpha\u20102b\/ribavirin combination therapy induces an anti\u2010viral effect in patients with chronic hepatitis C","volume":"52","author":"Murata K","year":"2005","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2003.03329.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"crossref","first-page":"9079","DOI":"10.1128\/jvi.70.12.9079-9082.1996","article-title":"Inhibition of viral replication reverses respiratory syncytial virus\u2010induced NF\u2010kappaB activation and interleukin\u20108 gene expression in A549 cells","volume":"70","author":"Fiedler MA","year":"1996","journal-title":"J. Virol."},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.10.5933-5947.2003"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00665.x"},{"key":"e_1_2_8_43_2","first-page":"315A","article-title":"Hepatic gene expression profiles during treatment with peginterferon and ribavirin: identifying important molecular pathways for treatment response","volume":"44","author":"Feld JJ","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160307"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80225-X"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260231"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2893.1998.00099.x"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2003.12.002"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811193392101"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)06088-1"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50218"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature03153"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.35950"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50364"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.19.438"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1053\/he.2000.5789"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00064-3"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hepres.2005.10.003"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544040-00006"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02741.x"},{"key":"e_1_2_8_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00029-0"},{"key":"e_1_2_8_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40757.x"},{"key":"e_1_2_8_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-005-0085-0"},{"key":"e_1_2_8_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2004.00490.x"},{"key":"e_1_2_8_66_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2006.01354.x"},{"key":"e_1_2_8_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-003-1363-9"},{"key":"e_1_2_8_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2004.03459.x"},{"key":"e_1_2_8_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-006-1858-2"},{"key":"e_1_2_8_70_2","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/357259"},{"key":"e_1_2_8_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-200402000-00004"},{"key":"e_1_2_8_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.12.016"},{"key":"e_1_2_8_73_2","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2002.36241"},{"key":"e_1_2_8_74_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.09.019"},{"key":"e_1_2_8_75_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00720.x"},{"key":"e_1_2_8_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(00)80314-1"},{"key":"e_1_2_8_77_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33711"},{"key":"e_1_2_8_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000182800.07794.01"},{"key":"e_1_2_8_79_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-004-0175-0"},{"key":"e_1_2_8_80_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-006-9293-5"},{"key":"e_1_2_8_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.10.008"},{"key":"e_1_2_8_82_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.014"},{"key":"e_1_2_8_83_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.011"},{"key":"e_1_2_8_84_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.07.022"},{"key":"e_1_2_8_85_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.02.015"},{"key":"e_1_2_8_86_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.05.016"},{"key":"e_1_2_8_87_2","first-page":"318A","article-title":"Improved virologic response rates with treatment extension to 72\u2003weeks of peginterferon alfa\u20102B plus weight\u2010based ribavirin in a difficult\u2010to\u2010treat population of genotype 1\u2010infected slow responders","volume":"44","author":"Pearlman B","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_88_2","first-page":"608A","article-title":"Extended treatment of 72 versus 48\u2003weeks for chronic hepatitis C patients with genotype 1 and high viral load using daily consensus interferon and ribavirin","volume":"44","author":"Kaiser P","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_89_2","first-page":"314A","article-title":"Improved sustained virological response (SVR) rates with higher, fixed doses of peginterferon alfa\u20102a (40KD) (PEGASYS\u00ae) plus ribavirin (COPEGUS\u00ae) in patients with \u2018difficult\u2010to\u2010cure\u2019 characteristics","volume":"44","author":"Fried MW","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_90_2","first-page":"316A","article-title":"Effect of drug exposure on sustained virological response in patients with chronic hepatitis C virus genotype 2 or 3 treated with peginterferon alfa\u20102a (40KD) (PEGASYS\u00ae) plus ribavirin (COPEGUS\u00ae) for 16 or 24\u2003weeks","volume":"44","author":"Shiffman ML","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_91_2","first-page":"336A","article-title":"Customizing treatment with peginterferon alfa\u20102a (40KD) (PEGASYS\u00ae) plus ribavirin (COPEGUS\u00ae) in patients with HCV genotype 1 or 4 infection: interim results of a prospective randomized trial","volume":"44","author":"Ferenci P","year":"2006","journal-title":"Hepatology"},{"key":"e_1_2_8_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21712"},{"key":"e_1_2_8_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08700.x"},{"key":"e_1_2_8_94_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.01.027"},{"key":"e_1_2_8_95_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20482"},{"key":"e_1_2_8_96_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20563"},{"key":"e_1_2_8_97_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/135965350300800108","article-title":"Normal erythropoietin response in chronic hepatitis C patients with ribavirin\u2010induced anaemia","volume":"8","author":"Durante Mangoni E","year":"2003","journal-title":"Antivir. Ther."},{"key":"e_1_2_8_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.07.057"},{"key":"e_1_2_8_99_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-004-1472-0"},{"key":"e_1_2_8_100_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i26.4013"},{"key":"e_1_2_8_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(99)00161-6"},{"key":"e_1_2_8_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.06041.x"},{"key":"e_1_2_8_103_2","doi-asserted-by":"publisher","DOI":"10.1089\/152308604771978318"},{"key":"e_1_2_8_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0899-9007(03)00095-9"},{"key":"e_1_2_8_105_2","first-page":"729","article-title":"A pilot study of eicosapentaenoic acid therapy for ribavirin\u2010related anemia in patients with chronic hepatitis C","volume":"11","author":"Ide T","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"e_1_2_8_106_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02260.x"},{"key":"e_1_2_8_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2005.05.014"},{"key":"e_1_2_8_108_2","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.51.419"},{"key":"e_1_2_8_109_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04378.x"},{"key":"e_1_2_8_110_2","first-page":"615A","article-title":"Eicosapentaenoic acid maintains ribavirin dose in HCV\u2010infected patients who treated with the combination therapy of pegylated interferon a plus ribavirin: a prospective, randomized controlled trial","volume":"44","author":"Takaki S","year":"2006","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1746.2008.05398.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1746.2008.05398.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T19:55:24Z","timestamp":1697399724000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1746.2008.05398.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":109,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["10.1111\/j.1440-1746.2008.05398.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1746.2008.05398.x","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]},"assertion":[{"value":"2008-06-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}